...approves therapies for ESRD patients with AF. Tecarfarin is an oral long-acting inhibitor of vitamin K epoxide reductase complex subunit 1 (VKORC1...
...Jacksonville, Fla.) said the compound is Phase III-ready. Elizabeth S. Eaton, Staff Writer tecarfarin (ati-5923) Espero Biopharma Inc. Vitamin K epoxide reductase complex subunit 1 (VKORC1...

...trial of tecarfarin as an anticoagulant. The product is an oral long-acting inhibitor of vitamin K epoxide reductase complex subunit 1 (VKORC1...

...open-label Phase III trial next half of anticoagulant tecarfarin, a long-acting inhibitor of vitamin K epoxide reductase complex subunit 1 ( VKORC1...

...Tecarfarin (formerly ATI-5923 ) Business: Cardiovascular Molecular target: Vitamin K epoxide reductase complex subunit 1 (VKORC1) Description: Long-acting inhibitor of vitamin K epoxide reductase complex subunit 1 (VKORC1...

...were genotyped for the cytochrome P450 family 2 subfamily C polypeptide 9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1...

...clinical use. In an cytochrome P450 family 2 subfamily C polypeptide 9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1...

...variants in the CYP2C19 gene, while the warfarin assay identifies patients with CYP2C9 and vitamin K epoxide reductase complex subunit 1 (VKORC1...

...methods to determine proper dosing of anti-coagulant warfarin. PharmiGene is now the global licensee of VKORC1-1639...

...diagnostic, which runs on the company's automated Verigene System, identifies variants of the CYP2C9 and VKORC1...

...Genetic Diagnostics Inc. , Bothell, Wash. Product: Warfarin GenoStat Test Business: Diagnostic Molecular target: Vitamin K epoxide reductase complex subunit 1 (VKORC1...